
|Articles|August 4, 2019
Avedro, Inc., company update: Epi-on crosslinking (CXL) and PiXL technology
Author(s)Julianne Mobilian
ICYMI: Here's what's in the 2019 pipeline
Advertisement
Rajesh Rajpal, MD, Chief Medical Officer of Avedro, Inc., provides a company update on Epi-on crosslinking (CXL) and PiXL technology during the 2019 ASCRS conference in San Diego.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves NDA labeling supplement allowing re-administration of iDose TR
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
Dr. Mali’s top 5 predictions in ophthalmology for 2026
4
Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula
5



























